Login / Signup

ABT-122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukin-17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate: A Randomized, Double-Blind Study.

Mark C GenoveseMichael E WeinblattJacob A AelionHeikki T MansikkaPaul M PelosoKun ChenYihan LiAhmed A OthmanAmit KhatriNasser S KhanRobert J Padley
Published in: Arthritis & rheumatology (Hoboken, N.J.) (2018)
Over the 12-week study period, dual inhibition of TNF and IL-17A with ABT-122 produced a safety profile consistent with that of adalimumb used for inhibition of TNF alone. The efficacy of ABT-122 over 12 weeks at dosages of 120 mg every other week or 120 mg every week was not meaningfully differentiated from that of adalimumab at a dosage of 40 mg every other week in patients with RA receiving concomitant methotrexate.
Keyphrases
  • rheumatoid arthritis
  • placebo controlled
  • double blind
  • high dose
  • clinical trial
  • study protocol
  • disease activity